中航高科(600862.SH):中航證券聚富優選2號近日增持202.07萬股 擬繼續增持不超7500萬元股份
格隆匯5月25日丨中航高科(600862.SH)公佈,2022年5月24日、5月25日,公司控股股東航空工業集團控股孫公司中航證券管理的中航證券聚富優選2號通過上海證券交易所集中競價交易系統增持公司股票202.07萬股,增持金額約為人民幣4836.29萬元,佔公司總股本的0.1451%。
中航證券聚富優選 2號擬自2022年5月24日起未來6個月內,繼續在二級市場以集中競價方式增持公司股票,累計增持金額不超過7500萬元(含2022年5月24日、5月25日增持金額)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.